Path: /mechanisms/senostatic-therapies-neurodegeneration
Senostatic therapies represent a complementary strategy to Senolytic Therapies for Neurodegenerative Diseases in addressing cellular senescence as a driver of neurodegeneration[1]. While senolytic drugs selectively eliminate senescent cells, senostatic agents suppress the harmful senescence-associated secretory phenotype (SASP) without killing the senescent cells themselves[2]. This approach may offer advantages in situations where complete senescent cell removal could have unintended consequences, or when the underlying senescence-inducing stress cannot be resolved[3].
The SASP includes pro-inflammatory cytokines (interleukin-6, interleukin-8, tumor necrosis factor-α), chemokines, growth factors, matrix metalloproteinases, and bioactive lipids that create a chronic neuroinflammatory environment[4]. In the aging brain, accumulation of senescent glial cells (microglia, astrocytes, oligodendrocyte progenitor cells) contributes to neuroinflammation, synaptic dysfunction, and progressive neuronal loss characteristic of Alzheimer's disease, Parkinson's disease, and related disorders[5]. Senostatic strategies aim to interrupt these deleterious signaling cascades while preserving the cells' defensive functions.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) serves as the master regulator of SASP transcription[6]. In senescent cells, persistent DNA damage response activation triggers NF-κB nuclear translocation, leading to transcription of SASP components[7]. The ATM/ATR kinases phosphorylate NEMO, activating the IKK complex, which then phosphorylates IκBα, releasing NF-κB for nuclear entry[8].
Multiple senostatic approaches target this pathway:
The mechanistic target of rapamycin (mTOR) pathway integrates (mTOR Signaling in Neurodegeneration) cellular nutrient and growth factor signals to promote SASP production through multiple mechanisms[12]. mTORC1 phosphorylates the translation repressor 4E-BP1, enabling translation of SASP mRNAs, while also regulating the NLRP3 Inflammasome in Neurodegeneration and IL-1β production[13].
Rapamycin and its analogs (rapalogs) (mTOR Inhibitors for Neurodegeneration) suppress SASP by inhibiting mTORC1 without inducing apoptosis in senescent cells[14]. Importantly, rapamycin does not prevent the cell cycle arrest characteristic of senescence—cells remain senescent but become metabolically "quiet" with reduced SASP secretion[15]. This dual action (SASP suppression + autophagy induction) makes rapamycin a particularly potent senostatic agent.
p38 mitogen-activated protein kinase (p38 MAPK) contributes to SASP regulation through both transcriptional and post-transcriptional mechanisms[16]. p38α MAPK phosphorylates the transcription factor C/EBPβ, which cooperates with NF-κB to drive SASP gene expression[17]. Additionally, p38 MAPK stabilizes SASP mRNAs through MK2-mediated phosphorylation of RNA-binding proteins[18].
SB203580 and SB239063 are selective p38 MAPK inhibitors that reduce SASP production in senescent fibroblasts and prevent SASP-induced paracrine senescence in neighboring cells[19]. In neurodegeneration models, p38 inhibitors have shown promise for reducing microglial activation and neuroinflammation[20].
Beyond direct SASP inhibition, alternative senostatic strategies aim to modulate the senescent phenotype itself:
In Alzheimer's disease, senescent microglia accumulate in regions of amyloid deposition and neurodegeneration, contributing to chronic neuroinflammation through SASP factors[24]. Senostatic approaches may reduce this neuroinflammation while preserving microglial phagocytic function needed for amyloid clearance[25]. Rapamycin has demonstrated benefits in multiple Alzheimer's disease models, reducing amyloid-β accumulation, tau pathology, and cognitive deficits through mechanisms including SASP suppression[26].
Senescent astrocytes and microglia accumulate in the substantia nigra and other brain regions affected by Parkinson's disease[27]. These cells produce SASP factors that promote α-synuclein aggregation, oxidative stress, and dopaminergic neuron death[28]. Senostatic interventions, particularly JAK-STAT inhibitors and rapamycin, have shown promise in preclinical Parkinson's disease models by reducing neuroinflammation and protecting dopaminergic neurons[29].
Senescent glial cells contribute substantially to motor neuron degeneration in ALS through SASP-mediated toxicity[30]. Studies in SOD1 mutant mice demonstrate that senescent astrocytes secrete pro-inflammatory factors that are directly toxic to motor neurons, and that senostatic treatment can reduce this toxicity and extend survival[31]. The JAK inhibitor ruxolitinib has been investigated in ALS clinical trials for its immunomodulatory effects[32].
Multiple system atrophy (MSA) features prominent glial cytoplasmic inclusions (GCIs) and extensive neuroinflammation driven by activated microglia and astrocytes[33]. Senescent glial cells likely contribute to the progressive neurodegeneration characteristic of MSA, making senostatic approaches particularly relevant for this disorder[34].
| Drug | Target | Clinical Status | Key Findings |
|---|---|---|---|
| Sirolimus (rapamycin) | mTORC1 | Phase 2 in AD | Safe; potential cognitive benefits |
| Everolimus (RAD001) | mTORC1 | Phase 2 in AD | Improved immune function; reduced Aβ |
| Temsirolimus | mTORC1 | Preclinical | Enhanced autophagy; neuroprotection |
The FDA-approved mTOR inhibitor sirolimus (rapamycin) has been studied for potential neuroprotective effects. A Phase 2 trial in Alzheimer's disease patients demonstrated safety and potential cognitive benefits, with associated biomarker changes suggesting reduced neurodegeneration[35].
Ruxolitinib, a JAK1/2 inhibitor approved for myelofibrosis, has demonstrated SASP-suppressing effects in preclinical studies[36]. An ALS clinical trial (NCT02948655) investigated ruxolitinib but did not meet its primary endpoint, though post-hoc analyses suggested potential benefits in certain patient subgroups[37].
The antidiabetic drug metformin exhibits senostatic properties through AMPK activation and subsequent mTOR inhibition[38]. Large observational studies suggest reduced dementia risk in diabetic patients treated with metformin[39]. The "Metformin in Alzheimer's Dementia Prevention" (MADE) trial is evaluating metformin's neuroprotective effects in non-diabetic patients with early Alzheimer's disease[40].
Combining senostatic and senolytic approaches may provide synergistic benefits by both reducing SASP production and eliminating existing senescent cells[41]. Rational combinations include:
Given the immunomodulatory effects of many senostatic agents, combinations with traditional anti-inflammatory approaches may enhance benefits:
Senostatic approaches offer several potential advantages:
Validating biomarkers of senescent cell burden and SASP activity will enable patient selection and treatment response monitoring:
Matching senostatic interventions to individual patients based on their dominant aging mechanism:
Combining senostatic agents with other therapeutic modalities may enhance efficacy in neurodegenerative diseases:
The mTOR Signaling in Neurodegeneration pathway intersects with multiple senostatic targets, making combination approaches particularly promising. Similarly, the NLRP3 Inflammasome in Neurodegeneration pathway represents a key SASP-related target that can be modulated by senostatic interventions.
See also: Senolytic Therapies for Neurodegenerative Diseases, Geroprotective Therapies for Neurodegeneration, mTOR Inhibitors for Neurodegeneration, NLRP3 Inhibitors in Neurodegeneration
Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2018. ↩︎
He S, Sharpless NE. Senescence in health and disease. Cell. 2017. ↩︎
van Deursen JM. The role of senescent cells in ageing. Nature. 2014. ↩︎
Coppé JP, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008. ↩︎
Baker DJ, Petersen RC. Cellular senescence in brain aging and neurodegenerative diseases. Lancet Neurol. 2018. ↩︎
Hayden MS, Ghosh S. 'NF-κB, the first quarter-century: remarkable progress and outstanding questions'. Genes Dev. 2012. ↩︎
Freund A, et al. Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell. 2011. ↩︎
Liu B, et al. DNA damage drives aging through inflammatory signaling. Nat Cell Biol. 2017. ↩︎
Herranz N, et al. mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype. Nat Cell Biol. 2015. ↩︎
Xu M, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and cognitive decline. Aging Cell. 2015. ↩︎
Tilstra JS, et al. NF-κB inhibition delays DNA damage-induced aging and SASP. Aging Cell. 2012. ↩︎
Laberge RM, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype. Nat Cell Biol. 2015. ↩︎
Wang R, et al. mTOR and NLRP3 inflammasome activation in senescence. Aging Cell. 2019. ↩︎
Blagosklonny MV. Rapamycin treatment of human cells. Cell Cycle. 2013. ↩︎
Demaria M, et al. An essential role for senescent cells in optimal wound healing. Dev Cell. 2014. ↩︎
Freytag S, et al. p38 MAPK regulates the SASP through C/EBPβ. Mol Cell. 2015. ↩︎
Wang W, et al. Targeting p38 MAPK for senostatic therapy. Nat Rev Drug Discov. 2019. ↩︎
Freund A, et al. Post-transcriptional regulation of the SASP. Genes Dev. 2011. ↩︎
Alimbetov D, et al. Suppression of the senescence-associated secretory phenotype. Aging Cell. 2016. ↩︎
Krementsov DN, et al. p38 MAPK and neuroinflammation. Neuropharmacology. 2014. ↩︎
Moiseeva O, et al. Metformin suppresses the senescence-associated secretory phenotype. Aging Cell. 2013. ↩︎
Xu M, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype. Aging Cell. 2015. ↩︎
Wang L, et al. PI3K inhibitors as senostatic agents. Oncotarget. 2018. ↩︎
Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer's disease. Biochem Pharmacol. 2014. ↩︎
Spangenberg EE, et al. Eliminating microglia in Alzheimer's disease. Nat Neurosci. 2019. ↩︎
Caccamo A, et al. mTOR regulates tau pathology in AD models. J Biol Chem. 2009. ↩︎
Fourrier C, et al. Microglial senescence in Parkinson's disease. J Parkinsons Dis. 2017. ↩︎
Reynolds A, et al. Senescent astrocytes in Parkinson's disease. Neurobiol Aging. 2019. ↩︎
Liu K, et al. Rapamycin protects dopaminergic neurons. J Neurol Sci. 2010. ↩︎
Trias E, et al. Senolytics eliminate senescent glia. Nat Neurosci. 2019. ↩︎
Ikeda M, et al. Senescent astrocytes in ALS. Exp Neurol. 2019. ↩︎
Paganoni S, et al. 'Ruxolitinib in ALS: a randomized controlled trial'. Lancet Respir Med. 2020. ↩︎
Stefanova N, et al. Microglia activation in multiple system atrophy. Acta Neuropathol. 2009. ↩︎
Wenning GK, et al. 'Multiple system atrophy: a review'. Lancet Neurol. 2012. ↩︎
Bove J, et al. 'Rapamycin in AD: phase 2 trial results'. J Alzheimers Dis. 2013. ↩︎
Xu M, et al. JAK inhibition as senostatic therapy. Aging Cell. 2015. ↩︎
Paganoni S, et al. Ruxolitinib in ALS. Lancet Respir Med. 2020. ↩︎
Moiseeva O, et al. Metformin suppresses SASP. Aging Cell. 2013. ↩︎
Kaeberlein M. Metformin and aging. Aging Cell. 2015. ↩︎
Luchsinger JA, et al. Metformin for dementia prevention. J Alzheimers Dis. 2017. ↩︎
Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2018. ↩︎
He S, Sharpless NE. Senescence in health and disease. Cell. 2017. ↩︎
Zhu Y, et al. Senolytic combinations for maximum effect. Aging Cell. 2016. ↩︎
Graber TG, et al. Rapamycin and anti-TNF combination therapy. Geroscience. 2019. ↩︎
Padhi AK, et al. Metformin and curcumin combination in neurodegeneration. Neuropeptides. 2019. ↩︎
van Deursen JM. The role of senescent cells in ageing. Nature. 2014. ↩︎
Blagosklonny MV. 'Rapamycin: one drug, many effects'. Cell Metab. 2014. ↩︎
Demaria M, et al. An essential role for senescent cells in wound healing. Dev Cell. 2014. ↩︎
He S, Sharpless NE. Senescence in health and disease. Cell. 2017. ↩︎
Xu M, et al. JAK inhibition and SASP rebound. Aging Cell. 2015. ↩︎
Kirkland JL, Tchkonia T. Clinical strategies for targeting senescent cells. Nat Rev Drug Discov. 2018. ↩︎
Ferrara M, et al. SASP factors as circulating biomarkers. J Gerontol A Biol Sci Med Sci. 2018. ↩︎
Masliah E, et al. Imaging senescent cells in the brain. Nat Neurosci. 2019. ↩︎
Horvath S. DNA methylation age of human tissues. Genome Biol. 2013. ↩︎
Blagosklonny MV. Targeting mTOR for senostatic therapy. Cell Cycle. 2013. ↩︎
Xu M, et al. JAK-STAT targeting in senescence. Aging Cell. 2015. ↩︎
Moiseeva O, et al. Metformin as senostatic agent. Aging Cell. 2013. ↩︎